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Xiao-Chai-Hu-Tang(XCHT),atraditionalChinesemedicineformulaconsistingofsevenmedicinalplants,isusedinthetreatment
ofvariousdiseases.WeshowherethatXCHTcouldprotecttype-1diabeticmiceagainstdiabeticnephropathy,usingstreptozotocin
(STZ)-induced diabetic mice and high-glucose (HG)-exposed rat mesangial cell (RMC) as models. Following 4 weeks of oral
administration with XCHT, renal functions and renal hypertrophy signiﬁcantly improved in the STZ-diabetic mice, while serum
glucose was only moderately reduced compared to vehicle treatment. Treatment with XCHT in the STZ-diabetic mice and HG-
exposed RMC resulted in a decrease in expression levels of TGF-β1, ﬁbronectin, and collagen IV, with concomitant increase in
BMP-7 expression. Data from DPPH assay, DHE stain, and CM-H2DCFDA analysis indicated that XCHT could scavenge free
radicals and inhibit high-glucose-induced ROS in RMCs. Taken together, these results suggest that treatment with XCHT can
improve renal functions in STZ-diabetic mice, an eﬀect that is potentially mediated through decreasing oxidative stress and
production of TGF-β1, ﬁbronectin, and collagen IV in the kidney during development of diabetic nephropathy. XCHT, therefore
merits further investigation for application to improve renal functions in diabetic disorders.
1.Introduction
Increasing prevalence of nephropathy and/or end-stage renal
disease (ESRD) in diabetic patients is becoming a serious
socialandhealthproblemworldwide[1,2].Hyperglycemiais
consideredasthemainfactortoinducediabeticnephropathy
(DN), and clinical strategies for management of DN include
glycemic control and blood pressure regulation [3, 4].
However, current therapeutic eﬀect for DN remains unsatis-
factory, thus resulting a year-by-year increase in the number
of diabetic patients with nephropathy [5]. Pathological
changes of DN are characterized by structural abnormalities
including renal-cell hypertrophy, increase in thickness of
glomerular basement membranes, and progressive accumu-
lation of extracellular matrix components [6].
Due to hyperglycemia, diabetes exhibits high oxidative
stress which depletes the activity of antioxidative defense
systemandinturnpromotesdenovofreeradicalsgeneration;
thus, strategies to reduce oxidative stress in diabetes mellitus
may exert favorable eﬀects on the progression of diabetic
glomerulosclerosis[7,8].Hyperglycemiaandoxidativestress
during DN induce abnormal production and stimulation
of TGF-β1-resident renal cells [4, 6, 8, 9]. TGF-β1 causes
augmented deposition of extracellular matrix proteins, such
as collagen IV and ﬁbronectin, in the glomeruli, thus
inducing mesangial expansion and glomerular basement
membranethickening[1].Therenalprotectiveprotein,bone
morphogenetic protein-7 (BMP-7), can reduce glomerular
and tubulointerstitial ﬁbrosis and prevent the pathogenesis
in diabetic nephropathy [10, 11]. Expression or treatment2 Evidence-Based Complementary and Alternative Medicine
Table 1: Constituents and proportions in 108g of XCHT.
Plant name and part Proportions (g)
Bupleuri chinense radix 28
Glycyrrhizae glabra L. radix 8
Panax ginseng C.A. Meyer radix 12
Pinellia ternate tuber 20
Scutellaria baicalensis Georgi radix 12
Zingiberis oﬃcinale Roscoe rhizoma 16
Zizyphus vulgaris LAM fructus 12
with recombinant BMP-7 has been shown to improve renal
damage from hyperglycemia-induced oxidative stress in the
kidney of diabetic animals [10, 12].
Xiao-Chai-Hu-Tang (Japanese name, Shosaiko-to) is a
herbal drug formula widely used in traditional Chinese
medicine and Japanese kampo medicine. XCHT consists of
a mixture of seven diﬀerent medicinal plants (Table 1)a n d
hasseveralexperimentallyprovenpharmacologicalactivities,
including prevention of experimental hepatotoxicity [13],
immunomodulatory eﬀect [14–16], antineoplastic activity
[17] and promotion of liver regeneration [18]. XCHT
has also been documented to decrease ﬁbrogenic protein
expression,includingTGF-β1andcollagen,toinhibithepatic
ﬁbrosis [19–21]. However, it remains unclear whether XCHT
has any renal protective activity during diabetic nephropathy
and could prevent streptozotocin (STZ)-induced type-1
diabetic mice from renal ﬁbrosis. We, therefore, investigated
the treatment eﬀect of XCHT on STZ-induced type-1
diabetic mice and high-glucose (HG)-exposed rat mesangial
cell(RMC)models.ExpressionlevelsofTGF-β1,ﬁbronectin,
collagen IV, and BMP-7 as well as antioxidative eﬀects of
XCHT treatment were examined in order to explore the
renal protective eﬀect and mechanism of XCHT in diabetic
nephropathy.
2.MaterialsandMethods
2.1. Preparation of Xiao-Chai-Hu-Tang Extract. The seven
diﬀerentconstituentmedicinalplantsofXiao-Chai-Hu-Tang
(XCHT) are listed in Table 1. They were purchased from a
herbalgroceryinKaohsiungcity,Taiwan.Theauthenticityof
these ingredients was conﬁrmed by Dr. M. H. Yen (Graduate
Institute of Natural Products, Kaohsiung Medical University,
Taiwan)usinghistologicaltechnique.XCHTwaspreparedby
mixing the appropriate proportions of the dried constituents
(Table 1). To prepare the aqueous extract of XCHT, 108g
of the dried material was extracted with 1liter of boiling
water for 2h. After the supernatant of the ﬁrst extraction
was removed, an additional 1liter of distilled water was
added and the sample was further subjected to another
2h of extraction. The same procedure was repeated for 3
times.Thedecoctionobtainedfromthethreeextractionswas
combined, ﬁltered, concentrated, and lyophilized. The yield
of the dried extract was about 38%, which was collected and
stored at −20◦C until use.
2.2. Animal Model for Diabetic Nephropathy. BALB/c mice,
8-week old, 18–20g in weight, were obtained from the
Animal Center of National Cheng Kung University Medical
College. STZ-diabetic mice were induced by intraperitoneal
(i.p.) injecting STZ (200mg/kg) (Sigma-Aldrich Inc., Saint
Louis, MO, USA) into fasting mice as described previously
[22]. Mice were considered to be diabetic if they had
elevated plasma glucose concentrations of 350mg/dL. All
experiments were carried out at 9 weeks after STZ injec-
tion. STZ-diabetic mice were considered to have diabetic
nephropathy (DN) when they had elevated levels of urea
nitrogen (BUN) and creatinine. All animal procedures were
performed according to the Guide for the Care and Use of
LaboratoryAnimalsoftheNationalInstitutesofHealth.Chang
Jung Christian University approved the animal care protocol
(IACUC approval no. CJCU-99-002) for the experiments
performed in this study. STZ-diabetic mice were treated with
200mg/kg of XCHT twice a day for four weeks. The vehicle
(distilledwater)usedtodisperseXCHTwasgivenatthesame
volume. The STZ-diabetic mice were divided into 3 groups
(n = 6), respectively: (1) Vehicle-treated normal mice; (2)
Vehicle-treated STZ-diabetic mice and (3) XCHT-treated
STZ-diabetic mice. At the end of the 4-week treatment, mice
were euthanized by cervical dislocation after pentobarbital
(40mg/kg, i.p.) anesthesia, and blood was collected from
their abdominal aorta for renal function analysis. Kidneys
were dissected and rinsed with cold isotonic saline and then
weighed, frozen in liquid nitrogen, and then kept for storage
at −80◦C for further analysis. An index of renal hypertrophy
was estimated by comparing the weight of the left kidney to
the body weight.
2.3.BloodGlucoseandRenalFunctionsDetermination. Blood
samples were collected before the treatments and one hour
after the last treatment for estimating the levels of plasma
glucose, BUN, and creatinine. Blood samples from the
mice were centrifuged at 3,000g for 10min. Samples were
incubated with reagents from glucose, BUN, or creatinine
kits (AppliedBio assay kits; Hercules, CA, USA), and the
levelsofbloodglucose,BUN,andserumcreatininewerethen
assessed by an autoanalyzer (Quik-Lab, Ames, Miles Inc.,
Elkhart, Indiana, USA), with samples run in duplicate.
2.4. Renal Histological Analysis. For morphometric analysis,
thekidneywasremovedandembeddedinparaﬃntoprepare
4-μmtissueslices.Thetissuesliceswerestainedwithperiodic
acid-Schiﬀ (PAS). The mesangial expansion index (MEI) was
scoredinfourlevelsfrom0to3,withtheindexscoresdeﬁned
as follows [23]: 0, normal glomeruli; 1, matrix expansion
occurred in up to 50% of a glomerulus; 2, matrix expansion
occurred in 50 to 75% of a glomerulus; 3, matrix expansion
occurredin75to100%ofaglomerulus.Scoreswereassigned
for at least 30 glomeruli from kidney slices from each mouse,
and the means were calculated. Each slide was scored by
a pathologist who was unaware of the experimental details.Evidence-Based Complementary and Alternative Medicine 3
3. Immunohistochemical Staining
Kidney sections were dewaxed and hydrated through graded
ethanol solutions and then rinsed with PBS. After treatment
f o r5 m i ni n3 %H 2O2 and 30min in blocking agent,
slides were incubated with primary antibodies of TGF-β1,
ﬁbronectin,collagenIV,orBMP-7(SantaCruz,USA)diluted
to 1:50 in PBS for 16h at 4◦C. Then, slides were washed
three times with PBS and incubated for 30min with biotin-
conjugated secondary antibodies (Vector, UK) for 1h. The
slides were washed again with PBS and the signal was
ampliﬁed with Vectastain ABC kit (Vector, UK). Finally,
the samples were developed using diaminobenzidine (DAB).
Hematoxylin was applied as the counter stain.
3.1. RMCs Cell Culture. Rat mesangial cell (RMC) line
was purchased from the American Type Culture Collection
(Manassas, VA, USA). RMCs were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Gibco-BRL, Gaithers-
burg, MD) containing 5mmol/L glucose supplemented with
15% FBS and antibiotics, and maintained at 37◦C in 95%
air, 5% CO2. We added 25mmol/L glucose (ﬁnal concen-
tration 30mmol/L) into serum-free DMEM for high-glucose
(HG) medium. DMEM without FBS and additional glucose
concentration solution were used as control medium. When
the cell monolayer reached about 60% conﬂuency, culture
medium was replaced with control or HG medium with dif-
ferent treatments and then cultured for 24h. XCHT (1,5, 10,
50μg/mL) and the free radical scavenger tiron (10mmol/L;
4,5-dihydroxyl-1,3-benzene disulfonic acid; Sigma-Aldrich
Inc., Saint Louis, MO, USA) [10, 12] were used for the
treatments.
3.2. Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR). RT-PCR was performed to determine the mRNA ex-
pressionlevelsofTGF-β1,ﬁbronectin,collagenIV,andBMP-
7. Total RNA of mouse kidney, or RMCs was extracted using
Trizol solution (Life Technologies) and subject- ed to reverse
transcription with StrataScript H-reverse transcriptase
(Stratagene, La Jolla, CA) to generate cDNA. Gene-speciﬁc
primer pairs (sense and antisense, resp.) used are as follows:
TGF-β1, F5 -CGGCAGCTGTACATTGACTT andR5 -TCA
GCTGCACTTGCAGGAG; ﬁbronectin,F5 -GAATCCAGT
CCACAGCCATTCCT andR5 -CCGCAGGTTGGA TGG
TGCGTG; collagen IV, F5 -CTGGCACAAAAGGGACGAG
and R5 -ACGTGGCCGAGAATTTCACC; BMP-7, F5 -
CTGGATGGGCAGAGCATCAA-3  andR5 -TGGTTG
GTGGCGTTC ATGTA-3 ; β-actin,F5 -GCTGGAAGG
ACAGCGAG-3  and R5 -TGGCATCGTGATGGACTCCG-
3 . PCR products were electrophoresed on 1.5% agarose gels
and stained with ethidium bromide. β-actin ampliﬁcation
was used as an internal control.
3.3. Western Blot Analysis for Kidney and RMCs. TGF-β1,
ﬁbronectin, collagen IV, and BMP-7 expression levels in
mousekidneyorRMCsweredeterminedbyWesternblotting
analysis. RIPA buﬀer was used to extract total protein. For
Western analysis, proteins were separated by SDS-PAGE,
transferred, and immobilized on a nitrocellulose membrane.
T h em e m b r a n ew a sb l o c k e dw i t h5 %n o n f a td r ym i l ki n
phosphate-buﬀered saline containing 0.1% Tween 20 (PBS-
T) for 2h at room temperature. The membrane was then
washed in PBS-T and hybridized with primary antibodies
diluted to proper concentration in PBS-T for 16h. Speciﬁc
antibodies (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) for TGF-β1, ﬁbronectin, collagen IV, BMP-7
(1:200 dilution), and β-actin (1:1000 dilution) were used.
Incubation with secondary antibodies and detection of the
antigen-antibody complex were performed using the ECL kit
(Amersham Biosciences, UK).
3.4. DPPH Radical Scavenging Assay. The antioxidant activ-
ity of XCHT and ascorbic acid (vitamin C) was measured
in terms of 1,1-diphenyl-2-picrylhydrazyl (DPPH) (Sigma-
Aldrich Inc., Saint Louis, MO, USA) free radical scavenging
ability. Vitamin C, an antioxidant, was used as a positive
control. The highest tested concentration of Vitamin C was
considered as 100% of scavenging activity. A solution of
XCHT at diﬀerentconcentrationswasplacedinacuvetteand
1mL of DPPH radical in methanol solution (23.7μg/mL)
was added, followed by incubation for 30min. The decrease
in absorbance at 517nm was determined with a spectropho-
tometer. All determinations were performed in triplicates.
The percent inhibition of DPPH radical by the samples was
calculated according to the following formula:
% of scavenging of DPPH =

1 −
A(s)
A(c)

× 100, (1)
whereA(c) is the absorbance of the control (without sample),
and A(s) is the absorbance of the sample at t = 30min.
3.5. Intracellular ROS Detection
3.5.1. DHE Staining. RMCs (10,000 cells) were seeded on
12-well cell culture plates and after 24h growth, the culture
medium was replaced with control (normal glucose, NG) or
high glucose (HG) medium in the presence or absence of
tiron (antioxidant control; 10mmol/L) or XCHT (20μg/mL)
for another 24-h incubation before being harvested. The
RMCs were ﬁxed with 3.7% paraformaldehyde for 30min,
washed three times with PBS, then stained with 5μmol/L of
dihydroethidium (DHE; Invitrogen) which acts as a ﬂuores-
cent indicator of ROS generated in response to the described
treatment. Images were acquired with an Olympus IX70
ﬂuorescence microscope ﬁtted with an Olympus America
camera, and analyzed with MagnaFire 2.1 software.
3.5.2. CM-H2DCFDA Analysis. Intracellular oxidative stress
was also measured by dichlorodihydroﬂuorescein diacetate
oxidation. Brieﬂy, 5,000 RMCs were plated in 96-well plates
overnight and washed twice with HBSS before experiments.
The cells were exposed to 20μM 5- (and -6)-chloromethyl-
2 ,7  -dichlorodihydroﬂuorescein diacetate, acetyl ester
(CM-H2DCFDA) (Invitrogen Life Technologies, Carlsbad,
CA,USA)for1handthentreatedwithnormal-glucose(NG)4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of XCHT on serum levels of glucose (a), BUN (b), and creatinine (c) in normal or STZ-diabetic mice after a 4-week XCHT
(200mg/kg) or vehicle (Veh) treatment. Mice were ﬁrst induced with STZ for 9 weeks to induce DN and then orally administered with
treatments. Values (mean ± SD) were obtained from 6 mice for each test group. #P<0.05 compared to the value of vehicle-treated normal
mice. ∗P<0.05 values from after 4 weeks of treatment compared to values prior treatment.
or HG medium combining with vehicle or diﬀerent concen-
trations of XCHT or 10μmol/L of tiron. The ﬂuorescence
wasreadimmediatelyatwavelengthsof485nmforexcitation
and 530nm for emission on a ﬂuorescence plate reader
(Fluoroskan Ascent; Thermo Electron Corporation, Milford,
MA, USA). The levels of ROS were calculated as percent
increases compared with the control, and the control was
normalized to 100% of the basal level.
3.6. Statistical Analysis. Results were expressed as mean ±
SD.StatisticalanalysiswascarriedoutbyusingANOVAanal-
ysis and Dunnett post hoc analysis. Statistical signiﬁcance
was achieved if P<0.05.
4. Results
4.1. XCHT Oral Administration Improves Renal Functions in
STZ-Diabetic Mice. Mice were injected with STZ to induce
type-1-like diabetic disease [22, 24]. After 9 weeks, the STZ-
injected mice developed typical features of diabetes neph-
ropathy, with serum levels of glucose, BUN, and creatinine
being signiﬁcantly higher than those observed in normal
mice (P<0.05) (Figures 1(a), 1(b) and 1(c))[ 25, 26].
In the absence of intervention (vehicle only), these three
blood chemistry parameters in the vehicle-treated STZ-
diabetic mice increased signiﬁcantly when comparing with
levels prior to treatment initiation. In contrast, STZ-diabetic
mice that received XCHT had modest reduction in serum
glucose but a signiﬁcant decrease in serum levels of BUN and
creatininecomparedtothatinvehiclecontroltreatmentafter
the 4-week oral administration (P<0.05) (Figures 1(a), 1(b)
and 1(c)).
At the end of the in vivo experiment, vehicle-treated
STZ-diabetic had enlarged kidneys, with the ratio of
kidney weight to body weight being signiﬁcantly higher
than that of normal mice (Figure 2(a)). XCHT treatment,
however, reduced the degree of renal hypertrophy in
the STZ-diabetic mice (P<0.05). When performing
histological analysis in the vehicle-treated normal mice,
the PAS stain shows nearly normal glomerular structure
with only mild mesangial expansion and no signiﬁcant
tubular damage (Figure 2(b) A). In contrast, there is an
increase in mesangial matrix, mesangial cellularity, and
capillary basement membrane thickening in thediabeticEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of XCHT on kidney hypertrophy of normal or STZ-diabetic mice after a 4-week XCHT (200mg/kg) or vehicle (Veh)
treatment. (a) The kidney/body weight ratio. Values (mean ± SD) were collected from 6 mice for each test group. (b) Representative
photomicrographs (original magniﬁcation, 200x) of PAS-stained kidney sections from STZ-diabetic mice receiving 4 weeks of XCHT or
vehicle treatment; (A) normal mice treated with vehicle, (B) STZ-diabetic mice treated with vehicle, and (C) STZ-diabetic mice treated
with XCHT. (c) Expansion of the glomerular matrix was scored as described in the text, and an average value was obtained from analyses
of 30 glomeruli in each mouse kidney. #P<0.05 values of STZ-diabetic mice compared to that of the normal mice. ∗P<0.05 values of
XCHT-treated STZ-diabetic mice compared to values from vehicle-treated STZ-diabetic mice.
mice that received vehicle treatment (Figure 2(b) B).
In particular, remarkable changes were observed in the
tubulointerstitial areas, including tubules dilation and
lined by ﬂattened epithelium. The glomerular hypertro-
phy is also prominent in the vehicle-treated STZ-diabetic
mice (Figure 2(b) B). These histological changes, however,
improved in the diabetic mice administered with XCHT,
which showed reduction in mesangial expansion, basement
membrane thickening, glomerular hypertrophy, and tubular
damage(Figure 2(b)C).Theseobservationsarealsoreﬂected
in the index of the glomerular matrix expansion assessed in
each mice group (Figure 2(c)). Thus, XCHT treatment can
eﬀectivelyimproverenalfunctionsandpreventkidneyinjury
in diabetic mice induced by STZ.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of XCHT on TGF-β1, ﬁbronectin, collagen IV,
and BMP-7 expression in the kidney of normal or STZ-diabetic
mice after 4 weeks of treatment (n = 6i ne a c hg r o u p ) .( a )
The mRNA expression of TGF-β1, ﬁbronectin, collagen IV, and
BMP-7 in the kidney of mice was detected using RT-PCR. β-actin
mRNAexpressionwasincludedasinternalcontrol.(b)Westernblot
analysis of TGF-β1, ﬁbronectin, collagen IV, and BMP-7 expression
in the kidney of the test mice. Representative data are shown.
5. XCHT Treatment Reduces TGF-β1,
Fibronectin, and Collagen IV Expression
While Increasing BMP-7 Levels in
STZ-Diabetic Mice
In order to explore the underlying mechanisms in XCHT’s
renal protective eﬀects against diabetic nephropathy, changes
in the mice kidney expression of TGF-β1, ﬁbronectin, colla-
gen IV, and BMP-7 were assessed using RT-PCR and Western
blot analyses. Vehicle-treated STZ-diabetic mice showed
higher expression of TGF-β1, ﬁbronectin, and collagen IV
than in vehicle-treated normal mice (Figures 3(a) and 3(b)).
Furthermore, due to the diabetic induction, the expression
of BMP-7 in the diabetic mice receiving control treatment
was lower than that in the vehicle-treated normal mice. In
contrast, after 4 weeks of XCHT treatment in STZ-diabetic
mice, kidney expression of these markers reverted to levels
similar to vehicle-treated normal mice, with augmented
BMP-7 and reduced levels of TGF-β1, ﬁbronectin, and
collagen IV expression (Figures 3(a) and 3(b)). To further
validatetheaboveresults,renalimmunostainingforTGF-β1,
ﬁbronectin, collagen IV, and BMP-7 expression was carried
out on kidneys of the test mice. As shown in Figure 4, the
STZ-diabetic mice exhibited greater TGF-β1 immunostain-
ing in the glomeruli (Figure 4(b)) whereas XCHT-treated
mice showed reduced TGF-β1p r o t e i n( Figure 4(c)). The
expression of ﬁbronectin and collagen IV was observed to
accumulate in the glomeruli and interstitial space of STZ-
diabetic mice (Figures 4(e) and 4(h)) relative to that of the
normal mice (Figures 4(d) and 4(g)). Following the 4-week
treatment, however, the extent of ﬁbronectin and collagen IV
expression in the glomeruli and interstitial space of XCHT-
treated STZ-diabetic mice (Figures 4(f) and 4(i)) was clearly
less than in the vehicle-treated STZ-diabetic mice (Figures
4(e) and 4(h)). Compared to the strong immunostaining
of BMP-7 expression in normal mice (Figure 4(j)), STZ-
diabetic mice showed reduced immunostaining of BMP-
7( Figure 4(k)) and 4-week treatment with XCHT could
reverse the pathophysiological eﬀect by enhancing its expres-
sion (Figure 4(l)). From these results, it appears that XCHT
mediates its renal protective eﬀect on the pathophysiology of
diabetes in part by reducing proﬁbrotic protein expression
and increasing BMP-7 level.
5.1. XCHT Inhibits Oxidative Stress Induced by High-Glucose
Exposure in RMCs and Reduces Proﬁbrotic Factors While
IncreasingBMP-7Expression. Wehavepreviouslyshownthat
exposing RMCs to high-glucose (HG) medium raises ROS
production in these cells [12], and ROS induced by hyper-
glycemia can stimulate TGF-β1 and contribute to diabetes
nephropathy [6]. To further determine whether oxidative
stress is involved in XCHT’s renal protective mechanism
under diabetic condition, we evaluated the direct ROS
scavenging eﬀect of XCHT in HG-exposed RMCs. As shown
in the DPPH radical scavenging assay (Figure 5(a)), XCHT
could scavenge the free radicals directly in a concentration-
dependent manner similar to the antioxidant vitamin C.
The anti-oxidative ability of XCHT was further visualized by
DHE stain (Figure 5(b)) and measured by CM-H2DCFDA
staining (Figure 5(c)). In both instances, ROS was noted to
increase in RMCs under high-glucose exposure compared
with normal-glucose (NG) control (Figures 5(b) A, 5(b)
Ba n d5(c)), but its levels were markedly inhibited by
XCHT, similar to eﬀects observed with the antioxidant
tiron (Figures 5(b) C, 5(b) D, and 5(c)). XCHT also dose-
dependently reduced HG-stimulated ROS generation in the
RMCs (Figure 5(c)).Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Renal immunostaining for TGF-β1 (a)–(c), ﬁbronectin (d)–(f), collagen IV (g)–(i), and BMP-7 (j)–(l) expression in normal or
STZ-diabetic mice receiving 4 weeks of XCHT treatment (n = 6 per group). Original magniﬁcation, 200x. Representative micrographs are
shown.
To assess whether the antioxidant eﬀect from XCHT was
related to its renal protective eﬀects, we tested the mRNA
and protein expression of TGF-β1, ﬁbronectin, collagen IV,
and BMP-7 in RMCs exposed to HG medium (Figures 6(a)
and 6(b)). HG medium-treated RMCs showed lower levels
of BMP-7 and increased TGF-β1, ﬁbronectin, and collagen
IV expression compared to NG medium-cultured RMCs.
These eﬀects, however, were reversed using the antioxidant
tiron and XCHT treatments, whereby an enhancement in
BMP-7 and a decrease TGF-β1, ﬁbronectin, and collagen IV
expressions were observed (Figures 6(a) and 6(b)).
6. Discussion
Although the main clinical strategies for diabetic nephropa-
thy (DN) are glycemic control and blood pressure regulation
[3, 4], the therapeutic outcome remains unsatisfactory [5].
In the present study, we showed that XCHT could improve
the renal functions and renal hypertrophy while decreasing
serum glucose moderately in STZ-diabetic mice. Further-
more, we provide evidence that XCHT’s renal protective
mechanism in DN could potentially be mediated through
(1) decreasing oxidative stress and production of TGF-β1,
ﬁbronectin, and collagen IV, and (2) increasing BMP-7
expression in the kidney of STZ-diabetic mice and HG-
exposed RMCs.
Recent search for new antiﬁbrotic drugs has refocused
on herbal medicine [27]. XCHT is widely prescribed to
patients with liver cirrhosis for over a millennium in Asia,
and the formula is established based on traditional clinical
experience and practice [17, 18, 20]. TGF-β1i si n v o l v e di n
mediating the development of diabetic renal hypertrophy8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of XCHT on free radicals in glucose-exposed RMCs. (a) Direct free radical scavenging activity of XCHT determined by
the DPPH radical scavenging assay. Values represent the data of three independent experiments (SE < 0.05). Vitamin C was used as a
positive control compound. (b) Intracellular visualization of ROS in RMCs under diﬀerent treatments using DHE stains; (A) normal-
glucose medium, (B) high-glucose medium, (C) high-glucose medium containing XCHT (20μg/mL), (D) high-glucose medium containing
tiron (antioxidant control; 10mmol/L). (c) Quantitation of ROS generation in RMCs using CM-H2DCFDA assay. RMCs were cultured in
normal glucose (NG; 5mmol/L) or high-glucose (HG; 30mmol/L) medium in the presence of XCHT (1, 10, 20, and 50μg / m L )o rt i r o n
(10mmol/L) for 24h. #P<0.05 compared to NG., ∗P<0.05 compared to HG.
and is upregulated in diabetic kidney [28]. Hyperglycemia-
induced upregulation of TGF-β1 stimulates mesangial cell
proliferation and ECM induction (increased ﬁbronectin
and collagen production), which contributes to the major
pathological changes observed in DN [28]. Thus, TGF-β1
has been considered as a therapeutic target in DN and other
chronic kidney diseases [29]. XCHT has been documented
to inhibit hepatic expression of TGF-β1m R N Aa n dp r o t e i n
in many experimental ﬁbrogenic animal models [30, 31].
The in vivo results from the present study also indicated
that XCHT treatment could decrease TGF-β1, ﬁbronectin,
and collagen IV expression in the kidney of STZ-diabetic
mice. In addition, in vitro, the expression of these proﬁbrotic
proteins was also reduced by XCHT treatment in high-
glucose-exposed RMCs. Thus, XCHT treatment appears to
improve DN by reducing TGF-β1 and ECM production.
Oxidative stress induced by hyperglycemia is implicated
inthedevelopmentofDN[6].ROSgeneratedfromhigh-glu-
cose condition can stimulate a number of growth factors
and cytokines, including TGF-β1 ,a n dl e a dt oe x c e s s i v e
production and accumulation of ECM proteins [6, 9, 32].
In vitro studies have shown that mesangial cells are the
major source of free radicals after exposure to high-glucose
concentrations [4, 33]. Previously, XCHT has also beenEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: Eﬀect of XCHT on TGF-β1, ﬁbronectin, collagen IV,
and BMP-7 expression in RMCs. RMCs were cultured in normal-
glucose(NG;5mmol/L)orhigh-glucose(HG;30mmol/L)medium
in the presence of 50μg/mL of XCHT for 24h. (a) The mRNA
expressionofTGF-β1,ﬁbronectin,collagenIV,andBMP-7inRMCs
detected by RT-PCR. β-Actin mRNA expression is used as an
internal control. (b) Western blot analysis of TGF-β1, ﬁbronectin,
collagen IV, and BMP-7 expression in RMCs.
reported to reduce the extracellular concentration of free
radical by its O2
− and NO scavenging activity in LPS-
stimulated cells [34]. Similarly, our results from the DPPH
assay and intracellular ROS analyses have shown that not
only XCHT could directly scavenge free radicals, but it
could also decrease ROS generation in high glucose-exposed
RMCs. The inhibition of ROS production by XCHT sup-
posedly could prevent downstream stimulation of TGF-β1
activation and production, and ultimately avert the resulting
aberrant ECM deposition. The in vitro results from the
RMCs recapitulated our previous in vivo observations in
the STZ-diabetic mice (Figures 3 and 4). Thus, it appears
that the inhibitory eﬀects of XCHT on high-glucose-induced
ROS generation could potentially disturb stimulation of
TGF-β1 and the resulting ECM proteins accumulation,
thereby partly explaining the drug’s renal protective eﬀects
in diabetic nephropathy. Thus, the observed eﬀect of XCHT
in decreasing the ECM proteins in vitro and in vivo is likely
related to its antioxidative ability in impeding TGF-β1.
BMP-7 helps to maintain normal renal structure and
physiological function, and its expression is decreased in
damaged kidney [35]. During the development of DN,
hyperglycemia causes oxidative stress and leads to BMP-7
expression decrease in renal cells [10–12]. Exogenous and
overexpression of BMP-7 has been shown to improve renal
function and prevent glomerular sclerosis in diabetic rats
[12, 36]. The medicinal plant Angelica sinensis could also
prevent STZ-diabetic rat from DN through increasing renal
BMP-7expression[37].Ourstudyshowedthatreducedrenal
BMP-7 expression in STZ-diabetic mice could be reversed
by 4-week treatment with XCHT. Moreover, XCHT could
increase BMP-7 expression in high-glucose-exposed RMCs.
Our results therefore suggest that XCHT’s protective eﬀect
against DN is at least in part mediated by increasing renal
BMP-7 expression.
In conclusion, XCHT could prevent renal functions
through augmenting BMP-7 expression and reducing ROS
and ECM production. We suggest that XCHT could be
applied for handling diabetic nephropathy and merits fur-
therstudyforitsclinical applicationindiabetic nephropathy.
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